NEW YORK, June 7 (GenomeWeb News) - Underwriters of Alnylam Pharmaceuticals' initial public offering have exercised an over-allotment option, the company said today.

 

The underwriters have purchased an additional 750,000 shares of common stock at the IPO price of $6 per share, less an underwriting discount of $.42 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.